Bactrim DS 800-160, containing sulfamethoxazole and trimethoprim, combats bacterial infections through a synergistic mechanism. Sulfamethoxazole inhibits dihydropteroate synthase, a key enzyme in folic acid synthesis. Trimethoprim then blocks dihydrofolate reductase, further disrupting folic acid production. This dual blockade effectively halts bacterial growth and reproduction, targeting a wide range of Gram-positive and Gram-negative bacteria commonly associated with cellulitis.
Efficacy varies depending on the specific bacteria causing the cellulitis. Studies show Bactrim is highly effective against Staphylococcus aureus and Streptococcus pyogenes, frequently implicated in cellulitis cases. However, resistance is a growing concern, so bacterial culture and sensitivity testing are crucial for optimal treatment selection. Clinical response should be monitored closely, and alternative antibiotics considered if no improvement is seen within 72 hours.
Dosage and treatment duration depend on factors such as infection severity and patient response. A healthcare professional should always guide treatment. Common side effects include nausea, rash, and diarrhea. Serious adverse reactions, though less frequent, include blood disorders. Prompt medical attention is necessary for any concerning symptoms.
